metricas
covid
Buscar en
Neurología (English Edition)
Toda la web
Inicio Neurología (English Edition) Amyotrophic lateral sclerosis and myasthenia gravis overlap syndrome: 3 new case...
Información de la revista
Vol. 35. Núm. 8.
Páginas 595-597 (octubre 2020)
Visitas
4435
Vol. 35. Núm. 8.
Páginas 595-597 (octubre 2020)
Letter to the Editor
Open Access
Amyotrophic lateral sclerosis and myasthenia gravis overlap syndrome: 3 new cases
Esclerosis lateral amiotrófica y miastenia gravis (síndrome overlap): presentación de 3 nuevos casos
Visitas
4435
S. Santos-Lasaosa
Autor para correspondencia
ssantos@salud.aragon.es

Corresponding author.
, A. López-Bravo, M. Garcés-Redondo, S. Atienza-Ayala, P. Larrodé-Pellicer
Servicio de Neurología, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
Este artículo ha recibido

Under a Creative Commons license
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Tablas (1)
Table 1. Demographic and clinical characteristics of the patients.
Texto completo
Dear Editor:

The association of myasthenia gravis (MG) and amyotrophic lateral sclerosis (ALS) (overlap syndrome) is infrequent in clinical practice. The available evidence suggests that immunomodulatory therapy has a protective effect in the early stages of motor neuron disease (MND).1,2 We present 3 cases of this overlap syndrome; Table 1 summarises the characteristics of these patients.

Table 1.

Demographic and clinical characteristics of the patients.

Patient 
Sex 
Age of symptom onset (years)  52  77  73 
First symptoms  Ptosis/diplopia/dysphagia  Diplopia/dysphagia  Diplopia/dysphagia 
Time to MND symptom onset  6-8 months  10-12 months  5 months 
Time to diagnosis of overlap syndrome  24 months  15 months  7 months 
Anti-AChR antibodies  0.74  > 20  7.6 
Anti-MuSK antibodies  Negative  Negative  Negative 
Mediastinum CT  Normal thymus  Normal thymus  Normal thymus 

AChR: acetylcholine receptor; CT: computed tomography; M: man; MND: motor neuron disease; MuSK: muscle-specific receptor tyrosine kinase; W: woman.

Patient 1

The patient was a 52-year-old man with initial symptoms of bilateral ptsosis, diplopia, and dysphagia; 6-8 months later, he presented left brachial paresis with thenar atrophy, global hyperreflexia, and increased jaw jerk reflex. 3-Hz repetitive stimulation obtained a decrement of > 10% in the fifth potential in the abductor digiti minimi. Anti-acetylcholine receptor (anti-AChR) antibody titre was 0.74 (positive results, > 0.7), and remained stable in subsequent determinations. Fasciculations and denervation potentials were observed in an electromyography study (EMG) performed 4 months after the initial assessment. At 24 months, the patient met diagnostic criteria for class IIb MG3 and definite ALS, according to the El Escorial criteria.4

Patient 2

The patient was a 77-year-old man who developed dysphonia and neurogenic dysphagia with fatigue. He was initially diagnosed class IIb MG: anti-AChR antibody titre was > 20 and 3-Hz repetitive stimulation of the abductor digiti minimi obtained a decrement of > 10% in the fifth potential. Treatment was started with pyridostigmine and oral prednisone, with good clinical response; at 15 months, he presented atrophy of the shoulder and pelvic girdles and right quadriceps, and exacerbation of bulbar symptoms and hyperreflexia. The EMG revealed fasciculations and denervation potentials in the deltoids, medial head of the left gastrocnemius, and the left vastus, and in the tongue.

Patient 3

The patient was a 73-year-old woman with dysphonia, neurogenic dysphagia, fatigue, and exertion dyspnoea of progressive onset in the previous 2 months. 3-Hz repetitive stimulation of the facial and accessory nerves obtained a decrement of > 10% in the fifth potential. Anti-AChR antibody titre was 7.6. After diagnosis of class IIb MG,3 combined treatment with pyridostigmine and prednisone was started. Five months after onset, the patient presented anarthria. An EMG study revealed denervation activity and fasciculations in the masseter, tongue, right first interosseous muscle, abductor digiti minimi, and vastus lateralis. The subsequent clinical progression, with lack of response to treatment with immunoglobulins and plasmapheresis, as well as the findings of the neurophysiological study, confirmed the diagnosis of definite ALS.4

Discussion

This association is infrequent, with only 28 cases reported in the literature,1,5 and represents 2% of patients in our series. Both processes feature an immune-mediated pathogenic mechanism.6,7 A decrease in CD4+ Foxp3+ regulatory T cells (Tregs)8 has been described; levels of these cells are associated with ALS progression and altered nitric oxide synthesis.9 It is also reported that muscle and neuromuscular junction involvement may already be apparent in the initial stage of ALS.6,10,11

Mulder et al.12 describe a decrease in action potentials in patients with ALS, which varies according to muscle analysed.13 For example, Wang et al.14 observed a decrease > 10% in 43% of patients with ALS and in 70% of those with MG. This finding was associated with disease progression and predominantly affected proximal muscles (frequently the trapezius) in patients with ALS, whereas distal muscles showed greater involvement in MG.

When both entities coexist, MG symptoms are mainly ocular and bulbar. In these cases, immunomodulatory treatment should be considered as a diagnostic and therapeutic option.1 Furthermore, positive anti-AChR antibody titres have been reported in up to 5% of patients with ALS. Although the cause is unclear, this may be related to the early involvement of the neuromuscular junction, which may also explain the higher levels of anti–low-density lipoprotein receptor–related protein 4 (anti-LRP4) antibodies in this disease.1 Okuyama et al.15 detected higher titres during periods of more aggressive disease activity and lower titres in stages of clinical stability.

Therefore, we conclude that although the available evidence suggests that early treatment of symptoms of neuromuscular junction involvement improves survival in patients with ALS, diagnosis of ALS/MG overlap syndrome should only be considered when signs and symptoms of MND are observed in association with clinical signs of neuromuscular junction involvement (preferably ocular or bulbar signs) or positive titres of anti-AChR, anti-MuSK, or anti-LRP10 antibodies; and response to acetylcholinesterase inhibitors.1

References
[1]
H. Tai, L. Cui, Y. Guan, M. Liu, X. Li, Y. Huang, et al.
Amyotrophic lateral sclerosis and myasthenia gravis overlap syndrome: a review of two cases and the associated literature.
Front Neurol., 8 (2017),
[2]
I.P. Johnson, P. Longone.
Commentary: amyotrophic lateral sclerosis and myasthenia gravis overlap syndrome: a review of two cases and the associated literature.
Front Neurol., 8 (2017),
[3]
A. Jaretzki 3rd, R.J. Barohn, R.M. Ernstoff, H.J. Kaminski, J.C. Keesey, A.S. Penn, et al.
Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of America.
Neurology., 55 (2000), pp. 16-23
[4]
B.R. Brooks.
El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology research Group on Neuromuscular Diseases and the El Escorial “Clinical limits of amyotrophic lateral sclerosis” workshop contributors.
J Neurol Sci., 124 (1994), pp. 96-107
[5]
N. Kvirkvelia, R. Shakarishvili, T. Kanashvili.
Transformation of myasthenia gravis into amyotrophic lateral sclerosis or their concomitance? (case review).
Georgian Med News., 276 (2018), pp. 86-92
[6]
A. Malaspina, F. Puentes, S. Amor.
Disease origin and progression in amyotrophic lateral sclerosis: an immunology perspective.
Int Immunol., 27 (2015), pp. 117-129
[7]
M.R. Turner, R. Goldacre, S. Ramagopalan, K. Talbot, M.J. Goldacre.
Autoimmune disease preceding amyotrophic lateral sclerosis: an epidemiologic study.
Neurology., 81 (2013), pp. 1222-1225
[8]
R.K. Sheean, F.C. McKay, E. Cretney, C.R. Bye, N.D. Perera, D. Tomas, et al.
Association of regulatory T-cell expansion with progresion of amyotrophic lateral sclerosis: a study of humans and a transgenic mouse model.
JAMA., 75 (2018), pp. 681-689
[9]
S. Meinen, S. Li, M.A. Ruegg, A.R. Punga.
Fatigue and muscle atrophy in a mouse model of myasthenia gravis is paralleled by loss of sarcolemmal nNOS.
[10]
S.H. Appel, J.I. Engelhardt, J. Garcia, E. Stefani.
Immunoglobulins from animal models of motor neuron disease and from human amyotrophic lateral sclerosis patients passively transfer physiological abnormalities to the neuromuscular junction.
Prot Nat Acad Sci USA., 88 (1991), pp. 647-651
[11]
L. Li, W.C. Xiong, L. Mei.
Neuromuscular junction formation, aging and disorders.
Annu Rev Physiol., 80 (2018), pp. 159-188
[12]
D.W. Mulder, E.H. Lambert, L.M. Eaton.
Myasthenic síndrome in patients with amyotrophic lateral sclerosis.
Neurology., 9 (1959), pp. 627-631
[13]
T. Iwanami, M. Sonoo, Y. Hatanaka, K. Hokkoku, C. Oishi, T. Shimizu.
Decremental responses to repetitive nerve stimulation (RNS) in motor neuron disease.
Clin Neurophysiol., 122 (2011), pp. 2530-2536
[14]
Y. Wang, Z. Xiao, H. Chu, J. Liang, X. Wu, H. Dong, et al.
Correlations between slow-rate repetitive nerve stimulation and characteristics associated with amyotrophic lateral sclerosis in Chinese patients.
J Phys Ther Sci., 29 (2017), pp. 737-743
[15]
Y. Okuyama, T. Mizuno, H. Inoue, K. Kimoto.
Amyotrophic lateral sclerosis with anti-acetylcholine receptor antibody.
Intern Med., 36 (1997), pp. 312-315

Please cite this article as: Santos-Lasaosa S, López-Bravo A, Garcés-Redondo M, Atienza-Ayala S, Larrodé-Pellicer P. Esclerosis lateral amiotrófica y miastenia gravis (síndrome overlap): presentación de 3 nuevos casos. Neurología. 2020;35:595–597.

Copyright © 2019. Sociedad Española de Neurología
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos